Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diazepam in GAD65 Associated Epilepsy
NCT05361447Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diazepam in epilepsy, sponsored by Mayo Clinic. Primary endpoint: Change in seizure frequency at 3 months. Planned start Jan 2023; status: withdrawn.
02
Drugs
diazepam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05361447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361447.